Clinical trial NCT01144000: Daptomycin With Rifampin for Treatment of Staphylococcal Prosthetic Joint Infection
Official title: Efficacy and Safety of Daptomycin (With or Without Rifampin) in the Treatment of Staphylococcal Hip, Knee and Shoulder Prosthetic Joint Infection
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Staphylococcal Infections
Keywords: Prosthetic joint infection
daptomycin
staphylococcus
Lead sponsor: Centre Hospitalier Universitaire Vaudois
Sponsor class: OTHER
Collaborators: name: University of Lausanne Hospitals
name: Kantonsspital Liestal
name: Schulthess Klinik
First posted: 2010-06-15
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To determine the outcome and safety of a combined antimicrobial treatment involving daptomycin and surgical approach involving retention or short-interval two-stage exchange of the implant. Patients with hip, knee and shoulder Prosthetic Joint Infection (PJI) caused by methicillin-susceptible and methicillin-resistant staphylococci will be included and followed during 2 years.

Detailed description: In this prospective open observational clinical study (phase 2) patients with hip, knee and shoulder PJI (as defined below) caused by methicillin-susceptible and methicillin-resistant staphylococci will be included. An informed consent will be obtained prior to patient inclusion. Medical records will be prospectively abstracted for demographic characteristics, clinical, radiographic, laboratory and microbiologic data using a standardized case report form (CRF). After inclusion, intravenous daptomycin 10 mg/kg (calculated as actual body weight) is given once daily for 2-3 weeks, followed by oral rifampin-containing antibiotics for a total of 3 months (as outlined below).

Two surgical modalities will be applied according to the PJI treatment algorithm:

* Open debridement and retention of the prosthesis (change of mobile parts): daptomycin will be combined with rifampin.
* Two-stage exchange of the prosthesis with a short interval (2-3 weeks): daptomycin of the prosthesis: daptomycin will be used alone.

The decision whether the implant will be retained or removed is based on objective criteria of the treatment algorithm and is not subject to bias. All consecutive patients with a staphylococcal PJI infection of the hip, knee or shoulder prosthesis will be included, if no exclusion criterion is present, obviating the selection bias. Since not many specialized institutions are treating patients with PJI, we expect low number of patients.

Eligibility criteria: Inclusion Criteria:

1. Informed consent has been obtained;
2. Subject is 18-80 years of age;
3. Subject has a PJI of the hip, knee and shoulder prosthesis caused by Staphylococcus aureus or coagulase-negative staphylococci (CNS) susceptible to daptomycin and rifampin;
4. Surgical approach: Debridement and retention of the prosthesis OR a two-stage prosthesis exchange with a short interval (2-3 weeks). The selection of the surgical procedure is performed according to the PJI treatment algorithm;
5. Subject is willing to participate in the study, to follow protocol study treatment regimen, and to comply with all planned follow-up assessments;
6. Females of childbearing potential are willing to practice reliable birth control measures other than oral contraceptives (e.g., condoms or diaphragms together with a spermicidal foam or gel) and willing to undergo a urine pregnancy test prior to study entry.

Exclusion Criteria:

1. Significant renal insufficiency (creatinine clearance rate ≤30 ml/min, as determined by the Cockcroft-Gault equation at inclusion);
2. Significant hepatic dysfunction at inclusion (AST or ALT ≥4 x upper limit of normal value);
3. Elevated creatin phosphokinase (CPK) ≥2 x upper limit of normal value at inclusion
4. PJI caused by additional microorganism;
5. Non-adherence to the PJI treatment algorithm (see below);
6. Subject has been previously enrolled in the study or is currently enrolled in another investigational study previously enrolled in the study or is currently enrolled in another investigational study, which deviates from the treatment algorithm;
7. Subject had prior exposure to daptomycin within the past 3 months;
8. Allergy or intolerance to daptomycin or rifampin, known hypersensitivity;
9. Body mass index (BMI) \>45 kg/m²;
10. Subject is pregnant, nursing or lactating;
11. Inability to read and understand the participant's information.

Primary outcomes:
measure: Treatment efficacy (infection-free period)
timeFrame: During study and 2 years after
Secondary outcomes:
measure: Safety of daptomycin (incidence of side effects)
timeFrame: During study and 2 years after
measure: Population pharmacokinetic profile of antibiotics (daptomycin, rifampin) will be evaluated through concentration measurements in plasma and drainage fluid.
timeFrame: during treatment (12 weeks)
Other outcomes:
Locations:
city: Lausanne
country: Switzerland
facility: Centre hospitaliere universitaire vaudois (CHUV)
state: Vaud
city: Liestal
country: Switzerland
facility: Kantonsspital
city: Zurich
country: Switzerland
facility: Schulhess Clinic
Study officials:
affiliation: Centre hospitaliere universitaire vaudvoise (CHUV) University Hospital of Lausanne
name: Andrej Trampuz
role: PRINCIPAL_INVESTIGATOR
References: